Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $56.50.

A number of research analysts have commented on the stock. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Chardan Capital assumed coverage on shares of Monopar Therapeutics in a research note on Monday, June 23rd. They issued a “buy” rating and a $60.00 price target for the company. Finally, Piper Sandler restated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th.

Monopar Therapeutics Stock Down 4.0%

NASDAQ MNPR opened at $33.60 on Monday. The stock’s 50-day simple moving average is $36.75 and its two-hundred day simple moving average is $34.76. Monopar Therapeutics has a twelve month low of $1.72 and a twelve month high of $54.30. The company has a market capitalization of $205.63 million, a price-to-earnings ratio of -9.66 and a beta of 0.99.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.27. On average, equities analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the sale, the insider now owns 822,255 shares of the company’s stock, valued at $28,778,925. This trade represents a 3.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $23,435,000. Adage Capital Partners GP L.L.C. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $13,182,000. RA Capital Management L.P. bought a new position in Monopar Therapeutics during the 4th quarter valued at approximately $11,247,000. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics during the 4th quarter valued at approximately $3,694,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $2,861,000. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.